Since a new legal framework came into effect in December 2014 for regenerative medicine products and cell therapy, the environment has leant itself to breakthroughs in Japan for both R&D and the practical application of products. One product has already been approved by an expedited approval system and Healios, an iPS cell therapy startup, has succeeded in its initial public offering on the Tokyo Stock Exchange - MOTHERS. Additionally, the Japanese government has implemented new measures to foster smart cell industries which utilize the power of biotechnology. This session will provide a deeper understanding of the new Japanese regulatory enviroment and strategy for creating an in-country bioeconomy as well as discuss current trends regarding the iPS movement

Session ID: 9543

Educational Topics